This principle of targeting shared metabolic vulnerabilities may inform the development of multi-target therapeutic strategies for complex neurodegenerative diseases like PD
As the main antioxidant enzyme in plasma, GPx3 is the only extracellular enzyme in the GPx family that reduces ROS products during normal metabolism or oxidative damage [15]
Read review Dihexa for Autism Spectrum Disorder (ASD) The Campbell rs1858830 MET promoter C-allele autism finding (the strongest mechanistic anchor to Dihexa pharmacology), the January 2026 mGluR5 PET 16-23% lower availability, the December 2025 DAYBUE STIX (trofinetide) Rett approval, the March 2026 FDA leucovorin decision (CFD only, not autism), the 270,701 NHS open referrals breaching NICE NG142, and the ~700,000 UK autistic population
Headache Vyvanse may cause headaches in some people who take this drug
Additionally, anticipating aggressive promotion, Indias apex regulator has moved to curb surrogate advertising for GLP-1 drugs